Login Get Started
Browse
Shares
Healthcare
Healthcare Equipment & Supplies
Oxford Immunotec Global
Oxford Immunotec Global logo

OXFD - Oxford Immunotec Global Reuters News

$21.99 0.0  0.0%

Last Trade - 05/03/21

Sector
Healthcare
RiskRating
Balanced
Size
Mid Cap
Style
Momentum Trap
Market Cap £406.4m
Enterprise Value £290.3m
Revenue £41.4m
Position in Universe 3322nd / 6651
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions OXFD Dividends
Reuters News
All News Reuters News Company Announcements
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
8:28am News
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
Sat 8:28am News
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:51 PM
Sat 12:00am News
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
8th Feb News
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
8th Feb News
BRIEF-Oxford Immunotec Updates Their T-SPOT Discovery SARS-CoV-2 Kit, Include A New Panel To Detect T Cells Reactive To Endemic Coronaviruses
4th Feb News
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses
4th Feb News
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses
4th Feb News
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
14th Jan News
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
14th Jan News
BRIEF-Oxford Immunotec’s T-Spot® Discovery Sars-Cov-2 Test Is Used To Measure The Efficacy Of Valneva’S Vla2001 Covid-19 Vaccine Candidate In A Phase I/Ii Clinical Study
13th Jan News
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study
13th Jan News
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study
13th Jan News
BUZZ-U.S. STOCKS ON THE MOVE-Oxford Immunotec, Baidu, Xunlei
7th Jan News
BUZZ-Oxford Immunotec Global: Gains after takeover by PerkinElmer
7th Jan News
NASDAQ RESUMED AT 07:30 AM
7th Jan News
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
7th Jan News
U.S. RESEARCH ROUNDUP- Accenture, Dow, Skyline Champion
18th Dec '20 News
Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week
16th Dec '20 News
Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week
16th Dec '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.